Estimated reading time: 2 minutes
By the end of 2022, GEODIS had received the IATA CEIV Pharma certification in 7 additional sites in EUROPE on top of the already existing site in Amsterdam, Netherlands.
Having this certification ensures that facilities, equipment, operations and staff comply with the appropriate applicable standards, guidelines and regulations expected from a pharmaceutical manufacturer. This industry-wide standard aims to extend industry best practice and achieve a globally acceptable standardization. By forming a common baseline from existing regulation and standards, this certification ensures international and national compliance to safeguard product integrity while addressing specific air cargo needs in pharma logistics.
Pharma projects for GEODIS are looking extremely promising entering 2023 and will benefit further from IATA CEIV certification at the following sites in the Europe region: London, UK; Manchester, UK; Frankfurt, Germany; Arlanda, Sweden; Budapest, Hungary; Warsaw, Poland; Brussels, Belgium; and the already validated site in Amsterdam, Netherlands, which gained certification in December, 2021.
“Having 8 sites CEIV-certified within 1 year demonstrates the commitment of the EUROPE Region of GEODIS to pharma logistics excellence. Our goal is to be an essential part of the growing GEODIS pharma network worldwide for the sole benefit of our pharma customers and the patients using their products.”
Thomas Kraus, GEODIS President & CEO Europe.
DISCLAIMER: “Breakbulk.News publishes editorial content, including news, features and press releases supplied by third‑party companies, institutions and PR agencies. Third parties who submit material to us are solely responsible for ensuring that all text, images, logos and other content they provide are accurate and that they hold all necessary rights, licences and permissions for news use. By submitting content to Breakbulk.News, contributors represent and warrant that their material does not infringe the rights (including copyright and related rights) of any third party and agree to indemnify Breakbulk.News respecting any claims arising from their submissions. human-edited, AI-assist. If you believe any content on our site infringes your rights, please contact us at info@breakbulk.news with full details and we will investigate promptly. Breakbulk.News is a Trademark of Breakbulk News & Media B.V. in The Netherlands.”
